Value-based pricing

From 2014 all new branded drugs will be subject to a revised process of drug pricing known as value-based pricing. Prostate Cancer UK and thirteen other leading cancer charities are working together to help shape this change rather than simply watching it develop unchallenged. We commissioned research to ensure the views of people affected by cancer are put at the heart of the Government's new drug pricing policy.

Our report - Value-based pricing: Getting it right for people with cancer - sets out our key recommendations based on the findings of this research. We believe that our recommendations have an important role to play in ensuring that the new value-based pricing system genuinely reflects the needs and aspirations of the millions of people affected by cancer in the UK.

Working together

We look forward to working closely with the Government, the pharmaceutical industry and other key stakeholders in the coming months to bring about a system which genuinely reflects the views of people affected by cancer and the recommendations in this report.

Read Chief Executive Owen Sharp's latest blog entry on the importance of getting value-based pricing right.

You can view the appendices of the report by clicking on the links below.

Appendix 1
Appendix 2
Appendix 3
Appendix 4
Appendix 5
Appendix 6